The association between low-dose aspirin use and the incidence of colorectal cancer: A nationwide cohort study

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 4, 2013, Pages 432-439

  Huang, W K ^a   Chiou, M J ^a   Yu, K H ^a   Lin, Y C ^a   Yang, T S ^a   Chen, J S ^a   Kuo, C F ^a   See, L C ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TAIWAN; TIME FACTORS; YOUNG ADULT;

EID: 84880256910     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12388     Document Type: Article

References (44)

1. Center MM, Jemal A, Ward E,. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-94.
2. Sung JJ, Lau JY, Young GP, et al,. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008; 57: 1166-76.
3. Jemal A, Bray F, Center MM, et al,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Department of Health, Executive Yuan, R.O.C. (Taiwan). Cause of death statistics in Taiwan, 2011. Available at: http://www.doh.gov.tw/EN2006/DM/DM2. aspx?now-fod-list-no=12402&class-no=390&level-no=2. Accessed February 16, 2013.
5. Cooper K, Squires H, Carroll C, et al,. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-206.
6. Algra AM, Rothwell PM,. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-27.
7. Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-13.
8. Cook NR, Lee IM, Gaziano JM, et al,. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55.
9. Gann PH, Manson JE, Glynn RJ, et al,. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-4.
10. Rothwell PM, Wilson M, Elwin CE, et al,. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
11. Rosenberg L, Louik C, Shapiro S,. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998; 82: 2326-33.
12. Garcia-Rodriguez LA, Huerta-Alvarez C,. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12: 88-93.
13. Hoffmeister M, Chang-Claude J, Brenner H,. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007; 121: 1325-30.
14. Din FV, Theodoratou E, Farrington SM, et al,. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010; 59: 1670-9.
15. Chan AT, Giovannucci EL, Meyerhardt JA, et al,. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-23.
16. Allison M, Garland C, Chlebowski R, et al,. The association between aspirin use and the incidence of colorectal cancer in women. Am J Epidemiol 2006; 164: 567-75.
17. Larsson SC, Giovannucci E, Wolk A,. Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer 2006; 95: 1277-9.
18. Mahipal A, Anderson KE, Limburg PJ, et al,. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1785-90.
19. Chan AT, Giovannucci EL, Meyerhardt JA, et al,. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008; 134: 21-8.
20. Friis S, Poulsen AH, Sorensen HT, et al,. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control 2009; 20: 731-40.
21. Bosetti C, Rosato V, Gallus S, et al,. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-15.
22. Bureau of National Health Insurance. The National Health Insurance Statistics, 2010. Available at: http://www.nhi.gov.tw/English/webdata/webdata. aspx?menu=11&menu-id=296&webdata-id=1942&WD-ID=296. Accessed February 18, 2013.
23. Kleinbaum DG, Kupper LL, Morgenstern H,. Epidemiologic Research: Principles and Quantitative Methods (Industrial Health & Safety). New York: John Wiley & Sons, 1982.
24. Jinjuvadia R, Lohia P, Jinjuvadia C, et al,. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol 2013; 47: 33-44.
25. Yuhara H, Steinmaus C, Cohen SE, et al,. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 2011; 106: 1911-21.
26. Chan AO, Jim MH, Lam KF, et al,. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007; 298: 1412-9.
27. Poynter JN, Gruber SB, Higgins PD, et al,. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92.
28. Rostom A, Dube C, Lewin G, et al,. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146: 376-89.
29. Ruder EH, Laiyemo AO, Graubard BI, et al,. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011; 106: 1340-50.
30. Winawer SJ, Zauber AG, Ho MN, et al,. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-81.
31. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, et al,. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
32. Hao Y, Jemal A, Zhang X, et al,. Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995-2004 (United States). Cancer Causes Control 2009; 20: 1855-63.
33. Chang HC, Horng JT, Lin WC, et al,. Evaluation of the appropriate age range of colorectal cancer screening based on the changing epidemiology in the past 20 years in Taiwan. ISRN Gastroenterol 2012; 2012: 960867.
34. Chan AT, Arber N, Burn J, et al,. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res 2012; 5: 164-78.
35. Chang LC, Huang N, Chou YJ, et al,. Patterns of combined prescriptions of aspirin-Ginkgo biloba in Taiwan: a population-based study. J Clin Pharm Ther 2008; 33: 243-9.
36. Bonovas S, Filioussi K, Flordellis CS, et al,. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25: 3462-8.
37. Singh H, Mahmud SM, Turner D, et al,. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009; 104: 3015-23.
38. Patrono C, Baigent C, Hirsh J, et al,. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233S.
39. Serebruany VL, Steinhubl SR, Berger PB, et al,. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95: 1218-22.
40. Huang ES, Strate LL, Ho WW, et al,. A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS One 2010; 5: e15721.
41. Huang ES, Strate LL, Ho WW, et al,. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124: 426-33.
42. Weil J, Colin-Jones D, Langman M, et al,. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
43. McQuaid KR, Laine L,. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-38.
44. Steinhubl SR, Bhatt DL, Brennan DM, et al,. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009; 150: 379-86.